- 12/10/2020
- biogen files new drug application for aducanumab in japan
- 11/30/2020
- eisai to present latest data on perampanel at the 74th american epilepsy society annual meeting
- 11/30/2020
- eisai and wren therapeutics enter into research collaboration agreement for drug discovery for synucleinopathies
- 11/27/2020
- abbvie and eisai announce an approval for additional indication of humira®, a fully human anti-tnfα monoclonal antibody, for the treatment of pyoderma gangrenosum for the first time in the world
- 11/26/2020
- eisai commences “padico” smartphone application service in japan to support the daily lives of patients with parkinson’s disease
- 11/18/2020
- jyseleca® (filgotinib) for rheumatoid arthritis launches in japan
- 11/18/2020
- eisai selected for membership in dow jones sustainability asia pacific index 2020 for seventh time
- 11/10/2020
- lenvima® plus keytruda® demonstrated statistically significant improvement in progression-free survival, overall survival and objective response rate versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma
- 11/09/2020
- sysmex presents academic report with a view to creating a simple method of diagnosing alzheimer’s disease using blood
- 10/30/2020
- european medicines agency accepts biogen’s aducanumab marketing authorization application for alzheimer’s disease
